Skip to main content

Living diagnostics

The blog that connects you with the in vitro diagnostic world.

How Pharmacists Can Contribute to Antimicrobial Stewardship?

We asked Dr. Catherine Duggan, CEO of the International Pharmaceutical Federation, about what clinical pharmacists can do in their roles to contribute to and promote antimicrobial stewardship.
Read more

Latest articles

Swipe for more articles

  • March 26, 2024

    Precision matters: Navigating the landscape of quality control in biologics

    Humans have been using plant and animal derived products (biologics) to treat disease for thousands of years, but the advent of mass production in the 20th century enabled the growth of biologics as a recognized class of medicines. Unlike chemically derived medicines, which combine specific ingredients in an ordered process, biologics are typically very large, complex molecules or mixtures of molecules that are difficult to characterize.
  • March 21, 2024

    Tuberculosis Management Four Years After COVID-19 Crisis

    Tuberculosis (TB) fatalities continue to rise. In 2022, an estimated 10.6 million people fell ill with TB, compared to 10.3 million in 2021 and 10 million in 2020. The infectious disease killed 1.3 million people worldwide each year. In 2022, TB remained the second leading cause of death from an infectious disease, after COVID-19, and caused almost twice as many deaths as HIV/AIDS.
  • March 13, 2024

    Antimicrobial Resistance Makes It Harder to Treat Urinary Tract Infections and Increases Risk of Sepsis and AKI

    Antimicrobial resistant bacteria pose a major public health threat because they limit treatment options for infectious diseases. Common ailments like urinary tract infections (UTIs), which have often been easily and quickly cured by antibiotics historically, are becoming harder to treat due to resistant bacteria. Not only does this prolong discomfort for those suffering from UTIs, it also presents the danger that the infection may lead to a more serious condition.
  • February 28, 2024

    The Rise of Multi-Drug Resistant Candidiasis in COVID-19 Patients

    Data suggests that since the onset of the COVID-19 pandemic, there has been an increased prevalence of antimicrobial resistant infections and increases in healthcare-associated infections (HAIs). A recent study shows an alarming incidence of multidrug-resistant candidiasis in COVID-19 patients, which carries high morbidity and mortality rates. With this increasing prevalence of resistant infections, the utilization of surveillance tools such as whole genome sequencing (WGS) are critical in preventing the spread of these infections.